CD274 and triple-negative breast carcinoma: From molecular mechanisms to clinical treatment and prognosis, the most concerned keywords are “Immunotherapy”, “PD-L1”, “Triple-negative breast cancer”, “Tumor-infiltrating lymphocytes”, and “Expression”, indicating that the research focuses on the immunotherapy of TNBC and the expression of PD-L1 and tumor-infiltrating lymphocytes.